| Autor: |
Mangione, Carol M., Barry, Michael J., Nicholson, Wanda K., Cabana, Michael, Coker, Tumaini Rucker, Davidson, Karina W., Davis, Esa M., Donahue, Katrina E., Jaén, Carlos Roberto, Kubik, Martha, Li, Li, Ogedegbe, Gbenga, Pbert, Lori, Ruiz, John M., Silverstein, Michael, Stevermer, James, Wong, John B., US Preventive Services Task Force |
| Předmět: |
|
| Zdroj: |
JAMA: Journal of the American Medical Association; 10/11/2022, Vol. 328 Issue 14, p1438-1444, 7p |
| Abstrakt: |
Importance: Anxiety disorder, a common mental health condition in the US, comprises a group of related conditions characterized by excessive fear or worry that present as emotional and physical symptoms. The 2018-2019 National Survey of Children's Health found that 7.8% of children and adolescents aged 3 to 17 years had a current anxiety disorder. Anxiety disorders in childhood and adolescence are associated with an increased likelihood of a future anxiety disorder or depression.Objective: The US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for anxiety disorders in children and adolescents. This is a new recommendation.Population: Children and adolescents 18 years or younger who do not have a diagnosed anxiety disorder or are not showing recognized signs or symptoms of anxiety.Evidence Assessment: The USPSTF concludes with moderate certainty that screening for anxiety in children and adolescents aged 8 to 18 years has a moderate net benefit. The USPSTF concludes that the evidence is insufficient on screening for anxiety in children 7 years or younger.Recommendation: The USPSTF recommends screening for anxiety in children and adolescents aged 8 to 18 years. (B recommendation) The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for anxiety in children 7 years or younger. (I statement). [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
